Magnolia Capital Management’s BioNTech BNTX Stock Holding History

Magnolia Capital Management’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-500	Closed	-$129K	–	122
2021 Q4	$129K	Buy	+500	New	+$137K	0.1%	87

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Pendal Group Sydney, Australia $11.6B AUM 12.87% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Magnolia Capital Management's BNTX Position: Q1 2022 in Review

Magnolia Capital Management sold out of BioNTech (BNTX) in Q1 2022, closing a stake of 500 shares — an estimated $129K sold.

Magnolia Capital Management first reported a position in BNTX in Q4 2021 and held it in 1 quarter. The position peaked at $129K in Q4 2021. 287 funds tracked by Wall St. Rank hold BNTX as of Q1 2022.

Magnolia Capital Management reported no remaining BioNTech position as of Q1 2022 after selling out during the quarter.
Magnolia Capital Management sold 500 BioNTech shares in Q1 2022, an estimated $129K.
Magnolia Capital Management first reported a position in BioNTech in Q4 2021 and held it in 1 quarter.
Magnolia Capital Management's BioNTech position peaked at $129K in Q4 2021.
287 funds tracked by Wall St. Rank held BioNTech as of Q1 2022.

Based on Magnolia Capital Management's 13F filing for Q1 2022, filed 7 Apr 2022.